AdamJonathanSavitzMD

Assistant Attending Psychiatrist, NewYork-Presbyterian Hospital. Clinical Assistant Professor of Psychiatry (Courtesy), Weill Cornell Medical College, Cornell University.

Join to view full profile

Dr. Savitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Savitz's full profile

Already have an account?

Office
21 Bloomingdale Rd
White Plains, NY 10605
Phone+1 914-997-4394

Fax+1 914-682-6906

Education & Training

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1995 - 1998
David Geffen School of Medicine at UCLAClass of 1994

Certifications & Licensure

NY State Medical License 2001 - 2026

Clinical Trials

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia Start of enrollment: 2005 Sep 01
Completed
Phase 3

Publications & Presentations

PubMed

6 citations
Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 ran...
Adam Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews
Revista Brasileira De Psiquiatria. 2019-04-15
13 citations
Schizophrenia comorbid with panic disorder: evidence for distinct cognitive profiles.
Erica Kirsten Rapp, Mandi White-Ajmani, Daniel Antonius, Raymond R. Goetz, Jill M. Harkavy-Friedman
Psychiatry Research. 2012-05-30
34 citations
Genome-wide association study of paliperidone efficacy.
Qingqin Li, Nathan E. Wineinger, Dong-Jing Fu, Ondrej Libiger, Larry Alphs
Pharmacogenetics and Genomics. 2017-01-01

Journal Articles

The Open Translational Science in Schizophrenia (OPTICS) Project: An Open-Science Project Bringing Together Janssen Clinical Trial and NIMH Data
Eva C Guinan, Joseph S Ross, Adam J Savitz, Nature

Press Mentions

Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of NeuropsychopharmacologyDecember 8th, 2022
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive DisorderJuly 17th, 2024